股本结构
单位：万股
| 公告日期 | 2026-03-17 | 2026-01-23 | 2026-03-30 | 2025-12-17 | 2025-10-16 | 2025-08-13 |
|---|---|---|---|---|---|---|
| 证券总股本 | 114.46 | 4578.35 | 4526.84 | 4578.35 | 3573.97 | 3261.47 |
| 普通股本 | 9156700.95 | 9156700.95 | 9053687.95 | 9156700.95 | 7147946.15 | 6522946.15 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-03-31 | 2026-01-22 | 2025-12-31 | 2025-12-17 | 2025-10-16 | 2025-06-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：80000
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-01-23 | 9156700.95 | 未披露 | 定期报告 | 2026-01-22 |
| 2026-03-30 | 9053687.95 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital on conversion of convertible notes, related party
Issuance of shares for services
Vesting of restricted shares
|
2025-12-31 |
| 2025-12-17 | 9156700.95 | 未披露 |
更多>>
Shares Offered 10,043,774 ADSs by the company, representing 20,087,548,000 ordinary shares
|
2025-12-17 |
| 2025-10-16 | 7147946.15 | 未披露 |
更多>>
Shares Offered 3,125,000 ADSs by the company, representing 6,250,000,000 ordinary shares
|
2025-10-16 |
| 2025-08-13 | 6522946.15 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital on conversion of convertible notes, related party
Issuance of share capital for payments in kind
Vesting of restricted shares
|
2025-06-30 |
| 2025-05-06 | 6435273.95 | 未披露 | 定期报告 | 2025-05-06 |
| 2025-05-14 | 5775298.15 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of share capital related to financing, net of issuance costs
|
2025-03-31 |
| 2025-04-15 | 5318691.95 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of shares for services
Issuance of share capital related to acquisition of Peak Bio, Inc., net of issuance costs
Vesting of restricted shares
Shares withheld for payroll taxes
Issuance of share capital related to financing, net of issuance costs
|
2024-12-31 |
| 2024-11-19 | 4951711.55 | 未披露 | 定期报告 | 2024-11-15 |
| 2024-11-19 | 2428923.15 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Shares withheld for payroll taxes
|
2024-09-30 |
| 2024-09-06 | 2428923.27 | 未披露 | 定期报告 | 2024-08-31 |
| 2024-08-19 | 2390689.95 | 未披露 | 定期报告 | 2024-08-09 |
| 2024-08-19 | 2428923.27 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Shares withheld for payroll taxes
Vesting of restricted shares
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital for services
|
2024-06-30 |
| 2024-06-04 | 2348249.75 | 未披露 |
更多>>
May 31, 2024. Akari Therapeutics, Plc. Issued and sold 3,817,553 ADSs and Warrants to purchase up to 3,817,553 ADSs pursuant to the Purchase Agreement.
|
2024-05-31 |
| 2024-05-15 | 1584739.15 | 未披露 | 定期报告 | 2024-05-10 |
| 2024-05-15 | 1597312.13 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of share capital related to financing, net of issuance costs
Vesting of restricted shares
|
2024-03-31 |
| 2024-03-29 | 1584739.15 | 未披露 | 定期报告 | 2024-03-29 |
| 2024-03-29 | 1323431.53 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital for vendor services
Vesting of restricted shares
|
2023-12-31 |
| 2023-10-20 | 1130595.35 | 未披露 | 定期报告 | 2023-10-13 |
| 2023-09-29 | 1012232.15 | 未披露 |
更多>>
From December 31, 2022 to June 30, 2023
Issuance of share capital, net of issuance costs
Issuance of share capital upon vesting of restricted stock units
|
2023-06-30 |
| 2023-03-31 | 1011158.38 | 未披露 |
更多>>
Ordinary shares offered 2,666,666,700 shares by the company
|
2023-03-31 |
| 2023-05-01 | 744491.71 | 未披露 |
更多>>
From December 31, 2021 to September 14, 2022
Issuance of share capital, net of issuance costs
|
2022-09-14 |
| 2022-03-10 | 593491.71 | 未披露 |
更多>>
1.ADSs offered by 7,440,833 ADSs, representing 744,083,300 ordinary shares.
2.Unless otherwise indicated, the number of ordinary shares outstanding prior to and after this offering is based on 5,190,833,823 ordinary shares outstanding as of February 28, 2022
|
2022-03-10 |
| 2022-01-04 | 519083.38 | 未披露 |
更多>>
1.ADSs offered by the company 4,311,019 ADSs, representing 431,101,900 ordinary shares.
2.Unless otherwise indicated, the number of ordinary shares outstanding prior to and after this offering is based on 4,759,731,923 ordinary shares outstanding as of December 28, 2021.
|
2022-01-04 |
| 2021-08-30 | 475973.19 | 未披露 | 定期报告 | 2021-08-27 |
| 2021-09-22 | 396497.90 | 未披露 |
更多>>
From March 31, 2021 to June1, 2021
Issuance of share capital related to financing, net of issuance costs
|
2021-06-01 |
| 2021-04-21 | 384733.19 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Issuance of ordinary shares
Issuance of share capital for entering into 2020 Purchase Agreement with Aspire Capital
Issuance of share capital upon conversion of deferred shares
Exercise of warrants
|
2020-12-31 |
| 2020-11-16 | 384733.19 | 未披露 | 定期报告 | 2020-11-05 |
| 2020-09-01 | 338657.31 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital for entering into 2020 Purchase Agreement with Aspire Capital
Issuance of share capital upon the exercise of warrants
|
2020-06-30 |
| 2020-03-04 | 287289.55 | 未披露 |
更多>>
On February 13, 2020, February 19, 2020, February 20, 2020 and February 28, 2020, respectively, Akari Therapeutics, Plc (the “Company”) entered into definitive securities purchase agreements (the “Purchase Agreements”) with certain accredited investors, the majority of whom are existing investors of the Company, including Dr. Ray Prudo, the Company’s Chairman, providing for the issuance of an aggregate of 5,620,296 American Depositary Shares (the “ADSs”) in a private placement at $1.70 per ADS for aggregate gross proceeds of approximately $9.5 million. The offering initially closed on February 25, 2020 and a final closing was held on March 3, 2020.
|
2020-03-03 |
| 2020-03-31 | 224586.59 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Issuance of share capital related to financing, net of issuance costs
|
2019-12-31 |
| 2019-11-27 | 210086.59 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of share capital related to financing, net of issuance costs
|
2019-09-30 |
| 2019-07-03 | 188753.26 | 未披露 | 定期报告 | 2019-07-03 |
| 2019-08-29 | 165069.34 | 未披露 |
更多>>
from March 31, 2019 to June 28, 2019
Issuance of share capital related to financing, net of issuance costs
|
2019-06-28 |
| 2019-05-29 | 158569.34 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Issuance of share capital related to financing, net of issuance costs
|
2019-03-31 |
| 2018-11-15 | 158069.34 | 未披露 |
更多>>
From January 1, 2018 to September 30, 2018
Issuance of share capital to directors
Issuance of share capital related to financing, net of issuance costs
|
2018-09-30 |
| 2018-08-17 | 152569.34 | 未披露 | 定期报告 | 2018-08-03 |
| 2018-07-18 | 152569.34 | 未披露 |
更多>>
From December 31, 2016 to December 31, 2017
Issuance of share capital upon conversion of deferred shares
Issuance of share capital related to financing, net of issuance costs
|
2017-12-31 |
| 2017-08-10 | 117769.34 | 未披露 |
更多>>
from January 1, 2017 to June 30, 2017
Issuance of ordinary shares upon conversion of deferred shares
|
2017-06-30 |
| 2016-11-10 | 117769.34 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-04-28 | 117275.42 | 未披露 | 定期报告 | 2016-06-27 |
| 2015-11-23 | 117769.34 | 未披露 |
更多>>
from January 1, 2015 to September 30, 2015
Issuance of share capital related to acquisition
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital for advisory fees
|
2015-09-30 |
| 2015-02-11 | 5563.63 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Issuance of share capital, net ($ 0.60)
Issuance of shares to service provider
|
2014-12-31 |
| 2014-03-24 | 5556.13 | 未披露 | 定期报告 | 2014-03-20 |
| 2014-01-31 | 5356.13 | 未披露 | 定期报告 | 2014-01-31 |
| 2014-03-24 | 4022.80 | 未披露 |
更多>>
From December 31,2012 to December 31,2013
Issuance of share capital and warrants, net
Issuance of share capital, net
Classification of warrants from liability to equity as a result of investors exercise of most favored nation terms
Issuance of shares due to price protection provision
|
2013-12-31 |
From December 31, 2024 to December 31, 2025
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital on conversion of convertible notes, related party
Issuance of shares for services
Vesting of restricted shares
Shares Offered 10,043,774 ADSs by the company, representing 20,087,548,000 ordinary shares
Shares Offered 3,125,000 ADSs by the company, representing 6,250,000,000 ordinary shares
From March 31, 2025 to June 30, 2025
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital on conversion of convertible notes, related party
Issuance of share capital for payments in kind
Vesting of restricted shares
From December 31, 2024 to March 31, 2025
Issuance of share capital related to financing, net of issuance costs
From December 31, 2023 to December 31, 2024
Issuance of shares for services
Issuance of share capital related to acquisition of Peak Bio, Inc., net of issuance costs
Vesting of restricted shares
Shares withheld for payroll taxes
Issuance of share capital related to financing, net of issuance costs
From June 30, 2024 to September 30, 2024
Shares withheld for payroll taxes
From March 31, 2024 to June 30, 2024
Shares withheld for payroll taxes
Vesting of restricted shares
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital for services
May 31, 2024. Akari Therapeutics, Plc. Issued and sold 3,817,553 ADSs and Warrants to purchase up to 3,817,553 ADSs pursuant to the Purchase Agreement.
From December 31, 2023 to March 31, 2024
Issuance of share capital related to financing, net of issuance costs
Vesting of restricted shares
From December 31, 2022 to December 31, 2023
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital for vendor services
Vesting of restricted shares
From December 31, 2022 to June 30, 2023
Issuance of share capital, net of issuance costs
Issuance of share capital upon vesting of restricted stock units
Ordinary shares offered 2,666,666,700 shares by the company
From December 31, 2021 to September 14, 2022
Issuance of share capital, net of issuance costs
1.ADSs offered by 7,440,833 ADSs, representing 744,083,300 ordinary shares.
2.Unless otherwise indicated, the number of ordinary shares outstanding prior to and after this offering is based on 5,190,833,823 ordinary shares outstanding as of February 28, 2022
1.ADSs offered by the company 4,311,019 ADSs, representing 431,101,900 ordinary shares.
2.Unless otherwise indicated, the number of ordinary shares outstanding prior to and after this offering is based on 4,759,731,923 ordinary shares outstanding as of December 28, 2021.
From March 31, 2021 to June1, 2021
Issuance of share capital related to financing, net of issuance costs
from December 31, 2019 to December 31, 2020
Issuance of ordinary shares
Issuance of share capital for entering into 2020 Purchase Agreement with Aspire Capital
Issuance of share capital upon conversion of deferred shares
Exercise of warrants
From March 31, 2020 to June 30, 2020
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital for entering into 2020 Purchase Agreement with Aspire Capital
Issuance of share capital upon the exercise of warrants
On February 13, 2020, February 19, 2020, February 20, 2020 and February 28, 2020, respectively, Akari Therapeutics, Plc (the “Company”) entered into definitive securities purchase agreements (the “Purchase Agreements”) with certain accredited investors, the majority of whom are existing investors of the Company, including Dr. Ray Prudo, the Company’s Chairman, providing for the issuance of an aggregate of 5,620,296 American Depositary Shares (the “ADSs”) in a private placement at $1.70 per ADS for aggregate gross proceeds of approximately $9.5 million. The offering initially closed on February 25, 2020 and a final closing was held on March 3, 2020.
From December 31, 2018 to December 31, 2019
Issuance of share capital related to financing, net of issuance costs
from June 30, 2019 to September 30, 2019
Issuance of share capital related to financing, net of issuance costs
from March 31, 2019 to June 28, 2019
Issuance of share capital related to financing, net of issuance costs
from December 31, 2018 to March 31, 2019
Issuance of share capital related to financing, net of issuance costs
From January 1, 2018 to September 30, 2018
Issuance of share capital to directors
Issuance of share capital related to financing, net of issuance costs
From December 31, 2016 to December 31, 2017
Issuance of share capital upon conversion of deferred shares
Issuance of share capital related to financing, net of issuance costs
from January 1, 2017 to June 30, 2017
Issuance of ordinary shares upon conversion of deferred shares
from January 1, 2015 to September 30, 2015
Issuance of share capital related to acquisition
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital for advisory fees
from December 31, 2013 to December 31, 2014
Issuance of share capital, net ($ 0.60)
Issuance of shares to service provider
From December 31,2012 to December 31,2013
Issuance of share capital and warrants, net
Issuance of share capital, net
Classification of warrants from liability to equity as a result of investors exercise of most favored nation terms
Issuance of shares due to price protection provision